Yahoo
Canadian Sec - Delayed Quote CAD

Revive Therapeutics Ltd. (RVV.CN)

0.0200 +0.0050 (+33.33%)
At close: October 30 at 12:34:10 PM EDT
Chart Range Bar
Loading chart for RVV.CN
  • Previous Close 0.0150
  • Open 0.0200
  • Bid 0.0150 x --
  • Ask --
  • Day's Range 0.0200 - 0.0200
  • 52 Week Range 0.0050 - 0.0800
  • Volume 212,393
  • Avg. Volume 190,753
  • Market Cap (intraday) 8.714M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.

revivethera.com

--

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

RVV.CN
100.00%
S&P/TSX Composite index (^GSPTSE)
11.78%

1-Year Return

RVV.CN
100.00%
S&P/TSX Composite index (^GSPTSE)
18.03%

3-Year Return

RVV.CN
33.33%
S&P/TSX Composite index (^GSPTSE)
88.90%

5-Year Return

RVV.CN
95.79%
S&P/TSX Composite index (^GSPTSE)
69.32%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -272.83%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -1.02M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.83k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    191.8k

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: